KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Equity Income (2019 - 2025)

Royalty Pharma's Equity Income history spans 7 years, with the latest figure at $35.7 million for Q4 2025.

  • For Q4 2025, Equity Income rose 185.23% year-over-year to $35.7 million; the TTM value through Dec 2025 reached -$21.9 million, down 135.52%, while the annual FY2025 figure was -$21.9 million, 155.25% down from the prior year.
  • Equity Income for Q4 2025 was $35.7 million at Royalty Pharma, up from -$66.7 million in the prior quarter.
  • Across five years, Equity Income topped out at $93.9 million in Q3 2024 and bottomed at -$66.7 million in Q3 2025.
  • The 5-year median for Equity Income is -$186500.0 (2022), against an average of -$2.0 million.
  • The largest YoY upside for Equity Income was 5993.51% in 2024 against a maximum downside of 6020.0% in 2024.
  • A 5-year view of Equity Income shows it stood at -$30.1 million in 2021, then skyrocketed by 65.19% to -$10.5 million in 2022, then surged by 626.59% to $55.1 million in 2023, then tumbled by 175.99% to -$41.9 million in 2024, then skyrocketed by 185.23% to $35.7 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Equity Income are $35.7 million (Q4 2025), -$66.7 million (Q3 2025), and $2.7 million (Q2 2025).